The Correlation of Voriconazole Trough Plasma Levels With Genetic Polymorphism, Efficacy, and Safety Outcomes in Hematologic Malignancy Patients With Invasive Pulmonary Aspergillosis
The investigators are trying to establish that routine clinical practice for voriconazole
therapeutic drug monitoring can improve the efficacy and safety outcomes.
In Korean patients with hematologic malignancy, the investigators also want to propose the
optimal dosing guideline of voriconazole with different genetic polymorphisms.
Observational Model: Case-Only, Time Perspective: Prospective
Successful outcome at 12 weeks after voriconazole use
Successful outcome = complete response + partial response Unsuccessful outcome = stable disease + failure of therapy + indeterminate response
South Korea: Institutional Review Board